

Jorge Cortes

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/11531546/jorge-cortes-publications-by-year.pdf>

Version: 2024-04-09

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

393 papers	43,164 citations	110 h-index	199 g-index
399 ext. papers	47,493 ext. citations	5.8 avg, IF	6.92 L-index

#	Paper	IF	Citations
393	The effect of eltrombopag in managing thrombocytopenia associated with tyrosine kinase therapy in patients with chronic myeloid leukemia and myelofibrosis. <i>Haematologica</i> , 2021 , 106, 2853-2858	6.6	5
392	Third-line therapy for chronic myeloid leukemia: current status and future directions. <i>Journal of Hematology and Oncology</i> , 2021 , 14, 44	22.4	12
391	Review of New-Generation Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia. <i>Current Oncology Reports</i> , 2021 , 23, 91	6.3	3
390	CML Therapy: A Focus on Second- and Third-Generation Tyrosine Kinase Inhibitors. <i>Hematologic Malignancies</i> , 2021 , 61-76	0	
389	Chronic myeloid leukaemia. <i>Lancet, The</i> , 2021 , 398, 1914-1926	40	6
388	How to manage CML patients with comorbidities. <i>Hematology American Society of Hematology Education Program</i> , 2020 , 2020, 237-242	3.1	3
387	Salvage Therapy Outcomes in a Historical Cohort of Patients With Relapsed or Refractory Acute Myeloid Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020 , 20, e871-e882	2	6
386	The early achievement of measurable residual disease negativity in the treatment of adults with Philadelphia-negative B-cell acute lymphoblastic leukemia is a strong predictor for survival. <i>American Journal of Hematology</i> , 2020 , 95, 144-150	7.1	13
385	Long-term follow-up of lower dose dasatinib (50mg daily) as frontline therapy in newly diagnosed chronic-phase chronic myeloid leukemia. <i>Cancer</i> , 2020 , 126, 67-75	6.4	47
384	The Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of acute leukemia 2020 , 8,		2
383	Timing of allogeneic hematopoietic cell transplantation (alloHCT) for chronic myeloid leukemia (CML) patients. <i>Leukemia and Lymphoma</i> , 2020 , 61, 2811-2820	1.9	3
382	Phase I/II study of dasatinib in combination with decitabine in patients with accelerated or blast phase chronic myeloid leukemia. <i>American Journal of Hematology</i> , 2020 , 95, 1288-1295	7.1	10
381	How to manage CML patients with comorbidities. <i>Blood</i> , 2020 , 136, 2507-2512	2.2	6
380	Chronic Myeloid Leukemia 2020 , 1836-1849.e2		
379	Treatment patterns and deep molecular response in chronic phase - chronic myeloid leukemia patients treated with second-line nilotinib or dasatinib: a multi-country retrospective chart review study. <i>Leukemia and Lymphoma</i> , 2020 , 61, 98-107	1.9	5
378	Chronic myeloid leukemia 2019 , 71-86		1
377	Outcomes of patients with chronic phase chronic myeloid leukemia (CML-CP) after discontinuation of frontline ponatinib therapy. <i>Leukemia and Lymphoma</i> , 2019 , 60, 3172-3180	1.9	2

376	Laying the foundation for genomically-based risk assessment in chronic myeloid leukemia. <i>Leukemia</i> , 2019 , 33, 1835-1850	10.7	50
375	Prognostic significance of baseline FLT3-ITD mutant allele level in acute myeloid leukemia treated with intensive chemotherapy with/without sorafenib. <i>American Journal of Hematology</i> , 2019 , 94, 984-991	7.1	22
374	Inotuzumab ozogamicin in combination with low-intensity chemotherapy (mini-HCVD) with or without blinatumomab versus standard intensive chemotherapy (HCVD) as frontline therapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukemia: A propensity score analysis. <i>Cancer</i> , 2019 , 125, 2579-2586	6.4	35
373	Treatment with a 5-day versus a 10-day schedule of decitabine in older patients with newly diagnosed acute myeloid leukaemia: a randomised phase 2 trial. <i>Lancet Haematology</i> , 2019 , 6, e29-e37	14.6	62
372	Clinical resistance to crenolanib in acute myeloid leukemia due to diverse molecular mechanisms. <i>Nature Communications</i> , 2019 , 10, 244	17.4	63
371	Tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia: a single-institution experience. <i>Journal of Hematology and Oncology</i> , 2019 , 12, 1	22.4	119
370	New Tool for Monitoring Molecular Response in Patients With Chronic Myeloid Leukemia. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2019 , 27, 33-39	1.9	
369	Treatment-free remission with first- and second-generation tyrosine kinase inhibitors. <i>American Journal of Hematology</i> , 2019 , 94, 346-357	7.1	61
368	Outcomes with lower intensity therapy in TP53-mutated acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2018 , 59, 2238-2241	1.9	16
367	Design and rationale for the life after stopping tyrosine kinase inhibitors (LAST) study, a prospective, single-group longitudinal study in patients with chronic myeloid leukemia. <i>BMC Cancer</i> , 2018 , 18, 359	4.8	11
366	Early results of lower dose dasatinib (50 mg daily) as frontline therapy for newly diagnosed chronic-phase chronic myeloid leukemia. <i>Cancer</i> , 2018 , 124, 2740-2747	6.4	32
365	Molecular Biology and Cytogenetics of Chronic Myeloid Leukemia 2018 , 29-47		2
364	Salvage Chemoimmunotherapy With Inotuzumab Ozogamicin Combined With Mini-Hyper-CVD for Patients With Relapsed or Refractory Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: A Phase 2 Clinical Trial. <i>JAMA Oncology</i> , 2018 , 4, 230-234	13.4	92
363	Sorafenib Combined with 5-azacytidine in Older Patients with Untreated FLT3-ITD Mutated Acute Myeloid Leukemia. <i>American Journal of Hematology</i> , 2018 , 93, 1136-1141	7.1	54
362	Outcome of patients with relapsed/refractory acute lymphoblastic leukemia after blinatumomab failure: No change in the level of CD19 expression. <i>American Journal of Hematology</i> , 2018 , 93, 371-374	7.1	53
361	Clinical experience with the BCL2-inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies. <i>American Journal of Hematology</i> , 2018 , 93, 401-407	7.1	229
360	Diagnosis and Treatment of Chronic Myelomonocytic Leukemias in Adults: Recommendations From the European Hematology Association and the European LeukemiaNet. <i>HemaSphere</i> , 2018 , 2, e150	0.3	48
359	Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: long-term follow-up of a single-centre, phase 2 study. <i>Lancet Haematology</i> , 2018 , 5, e618-e627	14.6	105

358	Chemoimmunotherapy with inotuzumab ozogamicin combined with mini-hyper-CVD, with or without blinatumomab, is highly effective in patients with Philadelphia chromosome-negative acute lymphoblastic leukemia in first salvage. <i>Cancer</i> , 2018 , 124, 4044-4055	6.4	62
357	Phase I studies of AZD1208, a proviral integration Moloney virus kinase inhibitor in solid and haematological cancers. <i>British Journal of Cancer</i> , 2018 , 118, 1425-1433	8.7	35
356	Frontline treatment of acute myeloid leukemia in adults. <i>Critical Reviews in Oncology/Hematology</i> , 2017 , 110, 20-34	7	68
355	Impact of achievement of complete cytogenetic response on outcome in patients with myelodysplastic syndromes treated with hypomethylating agents. <i>American Journal of Hematology</i> , 2017 , 92, 351-358	7.1	8
354	Systematic review and meta-analysis of standard-dose imatinib vs. high-dose imatinib and second generation tyrosine kinase inhibitors for chronic myeloid leukemia. <i>Journal of Cancer Research and Clinical Oncology</i> , 2017 , 143, 1311-1318	4.9	13
353	Pegylated interferon alfa-2a in patients with essential thrombocythaemia or polycythaemia vera: a post-hoc, median 83 month follow-up of an open-label, phase 2 trial. <i>Lancet Haematology</i> , 2017 , 4, e165-e175	14.6	74
352	Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 study. <i>Lancet Oncology</i> , 2017 , 18, 1061-1075	21.7	305
351	TP53 mutation does not confer a poor outcome in adult patients with acute lymphoblastic leukemia who are treated with frontline hyper-CVAD-based regimens. <i>Cancer</i> , 2017 , 123, 3717-3724	6.4	9
350	Ph-like acute lymphoblastic leukemia: a high-risk subtype in adults. <i>Blood</i> , 2017 , 129, 572-581	2.2	191
349	Phase 1 dose-finding study of rebastinib (DCC-2036) in patients with relapsed chronic myeloid leukemia and acute myeloid leukemia. <i>Haematologica</i> , 2017 , 102, 519-528	6.6	16
348	Significance of recurrence of minimal residual disease detected by multi-parameter flow cytometry in patients with acute lymphoblastic leukemia in morphological remission. <i>American Journal of Hematology</i> , 2017 , 92, 279-285	7.1	24
347	Safety and Efficacy of Blinatumomab in Combination With a Tyrosine Kinase Inhibitor for the Treatment of Relapsed Philadelphia Chromosome-positive Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017 , 17, 897-901	2	101
346	Randomized phase 2 study of low-dose decitabine vs low-dose azacitidine in lower-risk MDS and MDS/MPN. <i>Blood</i> , 2017 , 130, 1514-1522	2.2	102
345	Evaluation of cardiovascular ischemic event rates in dasatinib-treated patients using standardized incidence ratios. <i>Annals of Hematology</i> , 2017 , 96, 1303-1313	3	12
344	Combined targeting of BCL-2 and BCR-ABL tyrosine kinase eradicates chronic myeloid leukemia stem cells. <i>Science Translational Medicine</i> , 2016 , 8, 355ra117	17.5	93
343	Analysis of 2013 European LeukaemiaNet (ELN) responses in chronic phase CML across four frontline TKI modalities and impact on clinical outcomes. <i>British Journal of Haematology</i> , 2016 , 173, 114-126	4.5	12
342	Omacetaxine Mepesuccinate for Chronic Myeloid Leukemia. <i>Expert Review of Hematology</i> , 2016 , 9, 419-448	2.2	15
341	Clinical Safety and Efficacy of Nilotinib or Dasatinib in Patients With Newly Diagnosed Chronic-Phase Chronic Myelogenous Leukemia and Pre-Existing Liver and/or Renal Dysfunction. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016 , 16, 152-62	2	17

340	Acute myeloid leukemia: advancing clinical trials and promising therapeutics. <i>Expert Review of Hematology</i> , 2016 , 9, 433-45	2.8	7
339	Chronic Myeloid Leukemia 2016 , 1-11		2
338	The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of hematologic malignancies: multiple myeloma, lymphoma, and acute leukemia 2016 , 4, 90		14
337	Chronic myeloid leukemia: sequencing of TKI therapies. <i>Hematology American Society of Hematology Education Program</i> , 2016 , 2016, 164-169	3.1	9
336	Allogeneic Transplantation in First Remission Improves Outcomes Irrespective of FLT3-ITD Allelic Ratio in FLT3-ITD-Positive Acute Myelogenous Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2016 , 22, 1218-1226	4.7	42
335	Chronic myeloid leukemia: reminiscences and dreams. <i>Haematologica</i> , 2016 , 101, 541-58	6.6	61
334	Impact of BCR-ABL transcript type on outcome in patients with chronic-phase CML treated with tyrosine kinase inhibitors. <i>Blood</i> , 2016 , 127, 1269-75	2.2	87
333	Improving outcomes for patients with acute myeloid leukemia in first relapse: a single center experience. <i>American Journal of Hematology</i> , 2015 , 90, 27-30	7.1	28
332	Omacetaxine mepesuccinate in patients with advanced chronic myeloid leukemia with resistance or intolerance to tyrosine kinase inhibitors. <i>Leukemia and Lymphoma</i> , 2015 , 56, 120-7	1.9	25
331	Final report of a phase II study of imatinib mesylate with hyper-CVAD for the front-line treatment of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. <i>Haematologica</i> , 2015 , 100, 653-61	6.6	135
330	A Phase I/II Study of the mTOR Inhibitor Everolimus in Combination with HyperCVAD Chemotherapy in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia. <i>Clinical Cancer Research</i> , 2015 , 21, 2704-14	12.9	38
329	Use of second- and third-generation tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia: an evolving treatment paradigm. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015 , 15, 323-34 ²		100
328	Long-term molecular and cytogenetic response and survival outcomes with imatinib 400 mg, imatinib 800 mg, dasatinib, and nilotinib in patients with chronic-phase chronic myeloid leukaemia: retrospective analysis of patient data from five clinical trials. <i>Lancet Haematology,the</i> , 2015 , 2, e118-28	14.6	52
327	Secondary mutations as mediators of resistance to targeted therapy in leukemia. <i>Blood</i> , 2015 , 125, 3236-45	2.5	90
326	The role of ponatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia. <i>Expert Review of Anticancer Therapy</i> , 2015 , 15, 365-73	3.5	17
325	Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a single-centre, phase 2 study. <i>Lancet Oncology, The</i> , 2015 , 16, 1547-1555	21.7	188
324	Ponatinib as first-line treatment for patients with chronic myeloid leukaemia in chronic phase: a phase 2 study. <i>Lancet Haematology,the</i> , 2015 , 2, e376-83	14.6	71
323	BCR-ABL mutations in chronic myeloid leukemia treated with tyrosine kinase inhibitors and impact on survival. <i>Cancer Investigation</i> , 2015 , 33, 451-8	2.1	13

322	Progress in acute myeloid leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015 , 15, 139-51	2	33
321	Phase II study of methotrexate, vincristine, pegylated-asparaginase, and dexamethasone (MOPAD) in patients with relapsed/refractory acute lymphoblastic leukemia. <i>American Journal of Hematology</i> , 2015 , 90, 120-4	7.1	14
320	Incidence of and risk factors for involvement of the central nervous system in acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2015 , 56, 1392-7	1.9	37
319	Prognostic factors for outcome in patients with refractory and relapsed acute lymphocytic leukemia treated with inotuzumab ozogamicin, a CD22 monoclonal antibody. <i>American Journal of Hematology</i> , 2015 , 90, 193-6	7.1	33
318	Phase I/II trial of the combination of midostaurin (PKC412) and 5-azacytidine for patients with acute myeloid leukemia and myelodysplastic syndrome. <i>American Journal of Hematology</i> , 2015 , 90, 276-81	7.1	114
317	Targeted Therapies in Chronic Myeloid Leukemia 2015 , 111-120		
316	Bone marrow necrosis in acute leukemia: Clinical characteristic and outcome. <i>American Journal of Hematology</i> , 2015 , 90, 769-73	7.1	20
315	Results of phase 2 randomized study of low-dose decitabine with or without valproic acid in patients with myelodysplastic syndrome and acute myelogenous leukemia. <i>Cancer</i> , 2015 , 121, 556-61	6.4	99
314	Cardiovascular and pulmonary adverse events in patients treated with BCR-ABL inhibitors: Data from the FDA Adverse Event Reporting System. <i>American Journal of Hematology</i> , 2015 , 90, E66-72	7.1	42
313	Synergistic effects of p53 activation via MDM2 inhibition in combination with inhibition of Bcl-2 or Bcr-Abl in CD34+ proliferating and quiescent chronic myeloid leukemia blast crisis cells. <i>Oncotarget</i> , 2015 , 6, 30487-99	3.3	28
312	HCVAD plus imatinib or dasatinib in lymphoid blastic phase chronic myeloid leukemia. <i>Cancer</i> , 2014 , 120, 373-80	6.4	43
311	Investigational FMS-like tyrosine kinase 3 inhibitors in treatment of acute myeloid leukemia. <i>Expert Opinion on Investigational Drugs</i> , 2014 , 23, 943-54	5.9	25
310	Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION). <i>Blood</i> , 2014 , 123, 494-500	2.2	309
309	Practical issues surrounding the explosion of tyrosine kinase inhibitors for the management of chronic myeloid leukemia. <i>Blood Reviews</i> , 2014 , 28, 179-87	11.1	30
308	Predicting outcomes in patients with chronic myeloid leukemia at any time during tyrosine kinase inhibitor therapy. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2014 , 14, 327-334.e8	2	13
307	Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia. <i>Cancer Discovery</i> , 2014 , 4, 362-75	24.4	420
306	Phase I and extension study of clofarabine plus cyclophosphamide in patients with relapsed/refractory acute lymphoblastic leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2014 , 14, 231-8	2	11
305	Dynamics of chronic myeloid leukemia response to dasatinib, nilotinib, and high-dose imatinib. <i>Haematologica</i> , 2014 , 99, 1701-9	6.6	12

304	Chronic myeloid leukemia in adolescents and young adults: patient characteristics, outcomes and review of the literature. <i>Acta Haematologica</i> , 2014 , 132, 298-306	2.7	13
303	SL-401 and SL-501, targeted therapeutics directed at the interleukin-3 receptor, inhibit the growth of leukaemic cells and stem cells in advanced phase chronic myeloid leukaemia. <i>British Journal of Haematology</i> , 2014 , 166, 862-74	4.5	34
302	Phase II trial of hyper CVAD and dasatinib in patients with relapsed Philadelphia chromosome positive acute lymphoblastic leukemia or blast phase chronic myeloid leukemia. <i>American Journal of Hematology</i> , 2014 , 89, 282-7	7.1	41
301	Chronic Myeloid Leukemia 2014 , 1944-1957.e2		1
300	Retrospective analysis of prognostic factors associated with response and overall survival by baseline marrow blast percentage in patients with myelodysplastic syndromes treated with decitabine. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2013 , 13, 592-6	2	6
299	Cardiovascular toxicity of tyrosine kinase inhibitors. <i>Expert Opinion on Drug Safety</i> , 2013 , 12, 687-96	4.1	18
298	Chronic myeloid leukemia: overview of new agents and comparative analysis. <i>Current Treatment Options in Oncology</i> , 2013 , 14, 127-43	5.4	32
297	Analysis of the potential effect of ponatinib on the QTc interval in patients with refractory hematological malignancies. <i>Cancer Chemotherapy and Pharmacology</i> , 2013 , 71, 1599-607	3.5	21
296	Molecular analysis of patients with polycythemia vera or essential thrombocythemia receiving pegylated interferon α . <i>Blood</i> , 2013 , 122, 893-901	2.2	156
295	Targeted therapies in hematology and their impact on patient care: chronic and acute myeloid leukemia. <i>Seminars in Hematology</i> , 2013 , 50, 271-83	4	20
294	Omacetaxine mepesuccinate (synribo) - newly launched in chronic myeloid leukemia. <i>Expert Opinion on Pharmacotherapy</i> , 2013 , 14, 1977-86	4	7
293	Optimizing management of ruxolitinib in patients with myelofibrosis: the need for individualized dosing. <i>Journal of Hematology and Oncology</i> , 2013 , 6, 79	22.4	39
292	Trends in chronic myeloid leukemia incidence and survival in the United States from 1975 to 2009. <i>Leukemia and Lymphoma</i> , 2013 , 54, 1411-7	1.9	79
291	Decitabine can be safely reduced after achievement of best objective response in patients with myelodysplastic syndrome. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2013 , 13 Suppl 2, S289-94	2	2
290	Molecular Biology and Cytogenetics of Chronic Myeloid Leukemia 2013 , 29-44		1
289	Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia. <i>Cancer</i> , 2013 , 119, 2728-36	6.4	225
288	Outcome after failure of second generation tyrosine kinase inhibitors treatment as first-line therapy for patients with chronic myeloid leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2013 , 13, 477-84	2	19
287	The achievement of a 3-month complete cytogenetic response to second-generation tyrosine kinase inhibitors predicts survival in patients with chronic phase chronic myeloid leukemia after imatinib failure. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2013 , 13, 302-6	2	18

286	Phase II trials of tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia. <i>Expert Opinion on Orphan Drugs</i> , 2013 , 1, 607-623	1.1	
285	Novel treatment options for acute myelocytic leukemia. <i>Clinical Investigation</i> , 2013 , 3, 979-990		
284	Management of imatinib-resistant patients with chronic myeloid leukemia. <i>Therapeutic Advances in Hematology</i> , 2013 , 4, 103-17	5.7	74
283	Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation. <i>Blood</i> , 2013 , 121, 4655-62	2.2	296
282	Early responses predict better outcomes in patients with newly diagnosed chronic myeloid leukemia: results with four tyrosine kinase inhibitor modalities. <i>Blood</i> , 2013 , 121, 4867-74	2.2	110
281	The BCR-ABL T315I mutation compromises survival in chronic phase chronic myelogenous leukemia patients resistant to tyrosine kinase inhibitors, in a matched pair analysis. <i>Haematologica</i> , 2013 , 98, 1510-6	6.6	39
280	PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells. <i>Journal of Clinical Investigation</i> , 2013 , 123, 4144-57	15.9	170
279	A randomized study of 2 dose levels of intravenous clofarabine in the treatment of patients with higher-risk myelodysplastic syndrome. <i>Cancer</i> , 2012 , 118, 722-8	6.4	25
278	Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience. <i>Blood</i> , 2012 , 119, 1981-7	2.2	249
277	EUTOS score is not predictive for survival and outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors: a single institution experience. <i>Blood</i> , 2012 , 119, 4524-6	2.2	49
276	How I treat newly diagnosed chronic phase CML. <i>Blood</i> , 2012 , 120, 1390-7	2.2	88
275	Phase 2 study of subcutaneous omacetaxine mepesuccinate after TKI failure in patients with chronic-phase CML with T315I mutation. <i>Blood</i> , 2012 , 120, 2573-80	2.2	100
274	Epigenetic therapy is associated with similar survival compared with intensive chemotherapy in older patients with newly diagnosed acute myeloid leukemia. <i>Blood</i> , 2012 , 120, 4840-5	2.2	169
273	CML: the good, the better, and the difficult choices. <i>Blood</i> , 2012 , 120, 3866-7	2.2	4
272	Plasma exposure of imatinib and its correlation with clinical response in the Tyrosine Kinase Inhibitor Optimization and Selectivity Trial. <i>Haematologica</i> , 2012 , 97, 731-8	6.6	76
271	Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study. <i>Lancet Oncology</i> , 2012 , 13, 403-11	21.7	350
270	Dasatinib for the treatment of Philadelphia chromosome-positive leukemias. <i>Expert Opinion on Pharmacotherapy</i> , 2012 , 13, 2381-95	4	8
269	Molecular resistance: an early indicator for treatment change?. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2012 , 12, 79-87	2	3

268	Epigenetic therapy with hydralazine and magnesium valproate reverses imatinib resistance in patients with chronic myeloid leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2012 , 12, 207-12	2	26
267	Twice-daily fludarabine and cytarabine combination with or without gentuzumab ozogamicin is effective in patients with relapsed/refractory acute myeloid leukemia, high-risk myelodysplastic syndrome, and blast- phase chronic myeloid leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2012 , 12, 244-51	2	26
266	Phase I-II study of bendamustine in patients with acute leukemia and high risk myelodysplastic syndrome. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2012 , 12, 197-200	2	3
265	Nilotinib-associated vascular events. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2012 , 12, 337-40	2	99
264	Allogeneic hematopoietic cell transplantation for advanced polycythemia vera and essential thrombocythemia. <i>Biology of Blood and Marrow Transplantation</i> , 2012 , 18, 1446-54	4.7	19
263	Chronic myeloid leukemia: the race is yet to be won. <i>Cmaj</i> , 2012 , 184, 857-8	3.5	
262	Tyrosine kinase inhibitors in acute and chronic leukemias. <i>Expert Opinion on Pharmacotherapy</i> , 2012 , 13, 927-38	4	41
261	Estimations of the increasing prevalence and plateau prevalence of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy. <i>Cancer</i> , 2012 , 118, 3123-7	6.4	187
260	Reverse phase protein array profiling reveals distinct proteomic signatures associated with chronic myeloid leukemia progression and with chronic phase in the CD34-positive compartment. <i>Cancer</i> , 2012 , 118, 5283-92	6.4	27
259	Treatment options for chronic myeloid leukemia. <i>Expert Opinion on Pharmacotherapy</i> , 2012 , 13, 815-28	4	12
258	Analysis of outcomes in adolescents and young adults with chronic myelogenous leukemia treated with upfront tyrosine kinase inhibitor therapy. <i>Haematologica</i> , 2012 , 97, 1029-35	6.6	62
257	Outcome of treatment of chronic myeloid leukemia with second-generation tyrosine kinase inhibitors after imatinib failure. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2011 , 11 Suppl 1, S101-10	2	8
256	Patterns of molecular response to and relapse after combination of sorafenib, idarubicin, and cytarabine in patients with FLT3 mutant acute myeloid leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2011 , 11, 361-6	2	25
255	The clinical significance of achieving different levels of cytogenetic response in patients with chronic phase chronic myeloid leukemia after failure to front-line therapy: is complete cytogenetic response the only desirable endpoint?. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2011 , 11, 421-6	2	12
254	Chronic myeloid leukemia: mechanisms of resistance and treatment. <i>Hematology/Oncology Clinics of North America</i> , 2011 , 25, 981-95, v	3.1	34
253	Front-line and salvage therapies with tyrosine kinase inhibitors and other treatments in chronic myeloid leukemia. <i>Journal of Clinical Oncology</i> , 2011 , 29, 524-31	2.2	70
252	Dasatinib for the treatment of chronic myeloid leukemia. <i>Expert Review of Hematology</i> , 2011 , 4, 253-60	2.8	6
251	Pilot study of bortezomib for patients with imatinib-refractory chronic myeloid leukemia in chronic or accelerated phase. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2011 , 11, 355-60	2	15

250	Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results. <i>Blood</i> , 2011 , 117, 1141-5	2.2	296
249	Predictive factors for outcome and response in patients treated with second-generation tyrosine kinase inhibitors for chronic myeloid leukemia in chronic phase after imatinib failure. <i>Blood</i> , 2011 , 117, 1822-7	2.2	54
248	Results of allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia patients who failed tyrosine kinase inhibitors after developing BCR-ABL1 kinase domain mutations. <i>Blood</i> , 2011 , 117, 3641-7	2.2	51
247	Dynamics of chronic myeloid leukemia response to long-term targeted therapy reveal treatment effects on leukemic stem cells. <i>Blood</i> , 2011 , 118, 1622-31	2.2	52
246	The achievement of an early complete cytogenetic response is a major determinant for outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors. <i>Blood</i> , 2011 , 118, 4541-6; quiz 4759	2.2	115
245	Malignancies occurring during therapy with tyrosine kinase inhibitors (TKIs) for chronic myeloid leukemia (CML) and other hematologic malignancies. <i>Blood</i> , 2011 , 118, 4353-8	2.2	73
244	Outcome of patients with chronic myeloid leukemia with multiple ABL1 kinase domain mutations receiving tyrosine kinase inhibitor therapy. <i>Haematologica</i> , 2011 , 96, 918-21	6.6	15
243	Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyond. <i>Nature Reviews Drug Discovery</i> , 2011 , 10, 127-40	64.1	229
242	Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity. <i>Journal of Clinical Investigation</i> , 2011 , 121, 396-409	15.9	555
241	Burkitt lymphoma and atypical Burkitt or Burkitt-like lymphoma: should these be treated as different diseases?. <i>Current Hematologic Malignancy Reports</i> , 2011 , 6, 58-66	4.4	17
240	Role of tyrosine kinase inhibitors in the management of Philadelphia chromosome-positive acute lymphoblastic leukemia. <i>Current Hematologic Malignancy Reports</i> , 2011 , 6, 187-94	4.4	17
239	Immune modulation of minimal residual disease in early chronic phase chronic myelogenous leukemia: a randomized trial of frontline high-dose imatinib mesylate with or without pegylated interferon alpha-2b and granulocyte-macrophage colony-stimulating factor. <i>Cancer</i> , 2011 , 117, 572-80	6.4	41
238	Monitoring molecular response in chronic myeloid leukemia. <i>Cancer</i> , 2011 , 117, 1113-22	6.4	17
237	Long-term prognostic impact of the use of erythropoietic-stimulating agents in patients with chronic myeloid leukemia in chronic phase treated with imatinib. <i>Cancer</i> , 2011 , 117, 982-91	6.4	11
236	A phase 1-2 study of a farnesyltransferase inhibitor, tipifarnib, combined with idarubicin and cytarabine for patients with newly diagnosed acute myeloid leukemia and high-risk myelodysplastic syndrome. <i>Cancer</i> , 2011 , 117, 1236-44	6.4	30
235	Current event-free survival after sequential tyrosine kinase inhibitor therapy for chronic myeloid leukemia. <i>Cancer</i> , 2011 , 117, 327-35	6.4	17
234	Intolerance to tyrosine kinase inhibitors in chronic myeloid leukemia: Definitions and clinical implications. <i>Cancer</i> , 2011 , 117, 688-97	6.4	49
233	Long-term outcomes in the second-line treatment of chronic myeloid leukemia: a review of tyrosine kinase inhibitors. <i>Cancer</i> , 2011 , 117, 897-906	6.4	46

232	Experimental therapeutics for patients with myeloproliferative neoplasias. <i>Cancer</i> , 2011 , 117, 662-76	6.4	15
231	Experience with rituximab immunotherapy as an early intervention in patients with Rai stage 0 to II chronic lymphocytic leukemia. <i>Cancer</i> , 2011 , 117, 3182-6	6.4	11
230	Prognostic impact of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemia treated with nilotinib or dasatinib. <i>Cancer</i> , 2011 , 117, 5085-93	6.4	12
229	New developments in the treatment of chronic myeloid leukemia and Philadelphia-positive acute lymphoblastic leukemia. <i>Leukemia and Lymphoma</i> , 2011 , 52 Suppl 1, 81-91	1.9	10
228	Mutant BCR-ABL clones in chronic myeloid leukemia. <i>Haematologica</i> , 2011 , 96, 347-9	6.6	12
227	Does pretreatment fluorescence in situ hybridization for BCR-ABL predict imatinib-associated hematologic toxicity in chronic myeloid leukemia?. <i>Leukemia and Lymphoma</i> , 2011 , 52, 1010-6	1.9	5
226	Multivariable model for time to first treatment in patients with chronic lymphocytic leukemia. <i>Journal of Clinical Oncology</i> , 2011 , 29, 4088-95	2.2	105
225	Impact of treatment end point definitions on perceived differences in long-term outcome with tyrosine kinase inhibitor therapy in chronic myeloid leukemia. <i>Journal of Clinical Oncology</i> , 2011 , 29, 3173-8	2.2	44
224	Evolution of therapies for chronic myelogenous leukemia. <i>Cancer Journal (Sudbury, Mass)</i> , 2011 , 17, 465-76	2.6	37
223	Considerations in the management of patients with Philadelphia chromosome-positive chronic myeloid leukemia receiving tyrosine kinase inhibitor therapy. <i>Journal of Clinical Oncology</i> , 2011 , 29, 1512-6	2.2	24
222	The significance of major and stable molecular responses in chronic myeloid leukemia in the tyrosine kinase inhibitor era. <i>Revista Brasileira De Hematologia E Hemoterapia</i> , 2011 , 33, 455-60		1
221	A multinational study of health state preference values associated with chronic myelogenous leukemia. <i>Value in Health</i> , 2010 , 13, 103-11	3.3	28
220	Rapid clonal shifts in response to kinase inhibitor therapy in chronic myelogenous leukemia are identified by quantitation mutation assays. <i>Cancer Science</i> , 2010 , 101, 2005-10	6.9	11
219	Clinical impact of dose reductions and interruptions of second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukaemia. <i>British Journal of Haematology</i> , 2010 , 150, 303-12	4.5	34
218	Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia. <i>Journal of Clinical Oncology</i> , 2010 , 28, 3880-9	2.2	299
217	Healthcare resource utilization and costs associated with non-adherence to imatinib treatment in chronic myeloid leukemia patients. <i>Current Medical Research and Opinion</i> , 2010 , 26, 61-9	2.5	99
216	Nilotinib for the treatment of Philadelphia-chromosome-positive chronic myeloid leukemia. <i>Expert Opinion on Pharmacotherapy</i> , 2010 , 11, 3065-72	4	4
215	Phase I clinical and pharmacokinetic study of oral sapacitabine in patients with acute leukemia and myelodysplastic syndrome. <i>Journal of Clinical Oncology</i> , 2010 , 28, 285-91	2.2	64

214	miR-328 functions as an RNA decoy to modulate hnRNP E2 regulation of mRNA translation in leukemic blasts. <i>Cell</i> , 2010 , 140, 652-65	56.2	427
213	Chronic myeloid leukemia and second-generation tyrosine kinase inhibitors: when, how, and which one?. <i>Seminars in Hematology</i> , 2010 , 47, 344-53	4	10
212	Third-generation tyrosine kinase inhibitors and beyond. <i>Seminars in Hematology</i> , 2010 , 47, 371-80	4	17
211	Nilotinib for the treatment of chronic myeloid leukemia: An evidence-based review. <i>Core Evidence</i> , 2010 , 4, 207-13	4.9	23
210	Uncommon BCR-ABL kinase domain mutations in kinase inhibitor-resistant chronic myelogenous leukemia and Ph+ acute lymphoblastic leukemia show high rates of regression, suggesting weak selective effects. <i>Blood</i> , 2010 , 115, 5428-9	2.2	7
209	First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia. <i>Blood</i> , 2010 , 116, 2070-7	2.2	255
208	Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis. <i>Blood</i> , 2010 , 115, 1131-6	2.2	185
207	Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. <i>New England Journal of Medicine</i> , 2010 , 362, 2260-70	59.2	1197
206	Tyrosine kinase inhibitors: the first decade. <i>Current Hematologic Malignancy Reports</i> , 2010 , 5, 70-80	4.4	46
205	Chronic myeloid leukemia in the tyrosine kinase inhibitor era: what is the "best" therapy?. <i>Current Oncology Reports</i> , 2010 , 12, 302-13	6.3	24
204	Optimizing therapy for patients with chronic myelogenous leukemia in chronic phase. <i>Cancer</i> , 2010 , 116, 1419-30	6.4	35
203	Central nervous system prophylaxis in adults with acute lymphoblastic leukemia: current and emerging therapies. <i>Cancer</i> , 2010 , 116, 2290-300	6.4	51
202	Survival outcomes for clonal evolution in chronic myeloid leukemia patients on second generation tyrosine kinase inhibitor therapy. <i>Cancer</i> , 2010 , 116, 2673-81	6.4	42
201	Imatinib front-line therapy is safe and effective in patients with chronic myelogenous leukemia with pre-existing liver and/or renal dysfunction. <i>Cancer</i> , 2010 , 116, 3152-9	6.4	15
200	Phase 1 study of INNO-406, a dual Abl/Lyn kinase inhibitor, in Philadelphia chromosome-positive leukemias after imatinib resistance or intolerance. <i>Cancer</i> , 2010 , 116, 2665-72	6.4	39
199	Stem cell transplantation for patients with chronic myeloid leukemia resistant to tyrosine kinase inhibitors with BCR-ABL kinase domain mutation T315I. <i>Cancer</i> , 2010 , 116, 3631-7	6.4	20
198	Dasatinib in imatinib-resistant or imatinib-intolerant chronic myeloid leukemia in blast phase after 2 years of follow-up in a phase 3 study: efficacy and tolerability of 140 milligrams once daily and 70 milligrams twice daily. <i>Cancer</i> , 2010 , 116, 3852-61	6.4	96
197	Outcome of patients with myelodysplastic syndrome after failure of decitabine therapy. <i>Cancer</i> , 2010 , 116, 3830-4	6.4	195

196	Current patient management of chronic myeloid leukemia in Latin America: a study by the Latin American Leukemia Net (LALNET). <i>Cancer</i> , 2010 , 116, 4991-5000	6.4	19
195	Anthracycline dose intensification in adult acute lymphoblastic leukemia: lack of benefit in the context of the fractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimen. <i>Cancer</i> , 2010 , 116, 4580-9	6.4	16
194	ASH 2009 meeting report—Top 10 clinically oriented abstracts in acute leukemia. <i>American Journal of Hematology</i> , 2010 , 85, 277-280	7.1	0
193	Outcome of patients with FLT3-mutated acute myeloid leukemia in first relapse. <i>Leukemia Research</i> , 2010 , 34, 752-6	2.7	85
192	Chronic Myeloid Leukemia: Pathophysiology and Therapeutics 2010 , 139-153		
191	Lenalidomide plus prednisone results in durable clinical, histopathologic, and molecular responses in patients with myelofibrosis. <i>Journal of Clinical Oncology</i> , 2009 , 27, 4760-6	2.2	133
190	Significance of increasing levels of minimal residual disease in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in complete cytogenetic response. <i>Journal of Clinical Oncology</i> , 2009 , 27, 3659-63	2.2	52
189	Epidemiologic study on survival of chronic myeloid leukemia and Ph(+) acute lymphoblastic leukemia patients with BCR-ABL T315I mutation. <i>Blood</i> , 2009 , 114, 5271-8	2.2	87
188	Imatinib and beyond—exploring the full potential of targeted therapy for CML. <i>Nature Reviews Clinical Oncology</i> , 2009 , 6, 535-43	19.4	110
187	BCR-ABL truncation due to premature translation termination as a mechanism of resistance to kinase inhibitors. <i>Acta Haematologica</i> , 2009 , 121, 27-31	2.7	22
186	Triptolide induces cell death independent of cellular responses to imatinib in blast crisis chronic myelogenous leukemia cells including quiescent CD34+ primitive progenitor cells. <i>Molecular Cancer Therapeutics</i> , 2009 , 8, 2509-16	6.1	29
185	Characteristics associated with important clinical end points in patients with chronic lymphocytic leukemia at initial treatment. <i>Journal of Clinical Oncology</i> , 2009 , 27, 1637-43	2.2	67
184	Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase. <i>Journal of Clinical Oncology</i> , 2009 , 27, 4204-10	2.2	248
183	Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera. <i>Journal of Clinical Oncology</i> , 2009 , 27, 5418-24	2.2	317
182	Complexity of BCR-ABL kinase domain mutations during the course of therapy with tyrosine kinase inhibitors in chronic myeloid leukemia. <i>American Journal of Hematology</i> , 2009 , 84, 256-7	7.1	3
181	Efficacy of imatinib dose escalation in patients with chronic myeloid leukemia in chronic phase. <i>Cancer</i> , 2009 , 115, 551-60	6.4	97
180	Bleeding diathesis in patients with chronic myelogenous leukemia receiving dasatinib therapy. <i>Cancer</i> , 2009 , 115, 2482-90	6.4	98
179	Significance of suboptimal response to imatinib, as defined by the European LeukemiaNet, in the long-term outcome of patients with early chronic myeloid leukemia in chronic phase. <i>Cancer</i> , 2009 , 115, 3709-18	6.4	86

178	Dynamics and management of cytopenias associated with dasatinib therapy in patients with chronic myeloid leukemia in chronic phase after imatinib failure. <i>Cancer</i> , 2009 , 115, 3935-43	6.4	33
177	Synthetic tumor-specific breakpoint peptide vaccine in patients with chronic myeloid leukemia and minimal residual disease: a phase 2 trial. <i>Cancer</i> , 2009 , 115, 3924-34	6.4	50
176	Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily: two-year follow-up of a randomized phase 2 study (START-R). <i>Cancer</i> , 2009 , 115, 4136-47	6.4	168
175	Homoharringtonine, omacetaxine mepesuccinate, and chronic myeloid leukemia circa 2009. <i>Cancer</i> , 2009 , 115, 5382-93	6.4	102
174	Superior outcome with hypomethylating therapy in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome and chromosome 5 and 7 abnormalities. <i>Cancer</i> , 2009 , 115, 5746-51	6.4	83
173	Imatinib mesylate therapy for polycythemia vera: final result of a phase II study initiated in 2001. <i>International Journal of Hematology</i> , 2009 , 90, 58-63	2.3	9
172	Chronic myeloid leukemia in the tyrosine kinase inhibitor era: what is the best therapy?. <i>Current Oncology Reports</i> , 2009 , 11, 337-45	6.3	9
171	Treatment selection after imatinib resistance in chronic myeloid leukemia. <i>Targeted Oncology</i> , 2009 , 4, 3-10	5	44
170	The use of nilotinib or dasatinib after failure to 2 prior tyrosine kinase inhibitors: long-term follow-up. <i>Blood</i> , 2009 , 114, 4361-8	2.2	107
169	Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. <i>Journal of Clinical Oncology</i> , 2009 , 27, 6041-51	2.2	1019
168	Molecular biology of bcr-abl1-positive chronic myeloid leukemia. <i>Blood</i> , 2009 , 113, 1619-30	2.2	482
167	Prognostic significance of CD20 expression in adults with de novo precursor B-lineage acute lymphoblastic leukemia. <i>Blood</i> , 2009 , 113, 6330-7	2.2	149
166	Optimizing first-line therapy for patients with chronic myeloid leukemia. <i>Seminars in Hematology</i> , 2009 , 46, S5-10	4	1
165	Tyrosine kinase inhibitor-induced platelet dysfunction in patients with chronic myeloid leukemia. <i>Blood</i> , 2009 , 114, 261-3	2.2	151
164	Imatinib mesylate dose escalation is associated with durable responses in patients with chronic myeloid leukemia after cytogenetic failure on standard-dose imatinib therapy. <i>Blood</i> , 2009 , 113, 2154-60 ^{2.2}		135
163	Delayed achievement of cytogenetic and molecular response is associated with increased risk of progression among patients with chronic myeloid leukemia in early chronic phase receiving high-dose or standard-dose imatinib therapy. <i>Blood</i> , 2009 , 113, 6315-21	2.2	129
162	Failure to achieve a complete hematologic response at the time of a major cytogenetic response with second-generation tyrosine kinase inhibitors is associated with a poor prognosis among patients with chronic myeloid leukemia in accelerated or blast phase. <i>Blood</i> , 2009 , 113, 5058-63	2.2	21
161	Phase 3 study of dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-month median follow-up. <i>Blood</i> , 2009 , 113, 6322-9	2.2	137

160	Long-term outcome of patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors after imatinib failure is predicted by the in vitro sensitivity of BCR-ABL kinase domain mutations. <i>Blood</i> , 2009 , 114, 2037-43	2.2	103
159	Chronic myeloid leukemia (CML) with P190 BCR-ABL: analysis of characteristics, outcomes, and prognostic significance. <i>Blood</i> , 2009 , 114, 2232-5	2.2	122
158	Development and targeted use of nilotinib in chronic myeloid leukemia. <i>Drug Design, Development and Therapy</i> , 2009 , 2, 233-43	4.4	10
157	Phase I Dose-Escalation Trial of SB1518, a Novel JAK2/FLT3 Inhibitor, in Acute and Chronic Myeloid Diseases, Including Primary or Post-Essential Thrombocythemia/ Polycythemia Vera Myelofibrosis.. <i>Blood</i> , 2009 , 114, 3905-3905	2.2	28
156	A Phase I Evaluation of TG101348, a Selective JAK2 Inhibitor, in Myelofibrosis: Clinical Response Is Accompanied by Significant Reduction in JAK2V617F Allele Burden.. <i>Blood</i> , 2009 , 114, 755-755	2.2	19
155	Optimizing outcomes for patients with advanced disease in chronic myelogenous leukemia. <i>Seminars in Oncology</i> , 2008 , 35, S1-17; quiz S18-20	5.5	21
154	Nilotinib: a novel Bcr-Abl tyrosine kinase inhibitor for the treatment of leukemias. <i>Expert Opinion on Investigational Drugs</i> , 2008 , 17, 1127-36	5.9	11
153	Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. <i>Blood</i> , 2008 , 112, 975-80	2.2	568
152	Nilotinib: a phenylamino-pyrimidine derivative with activity against BCR-ABL, KIT and PDGFR kinases. <i>Future Oncology</i> , 2008 , 4, 611-21	3.6	21
151	Therapeutic options against BCR-ABL1 T315I-positive chronic myelogenous leukemia. <i>Clinical Cancer Research</i> , 2008 , 14, 4392-9	12.9	83
150	Phase II study of dasatinib in Philadelphia chromosome-negative acute and chronic myeloid diseases, including systemic mastocytosis. <i>Clinical Cancer Research</i> , 2008 , 14, 3906-15	12.9	136
149	Therapeutic options for patients with clonal and idiopathic hypereosinophilia. <i>Expert Opinion on Investigational Drugs</i> , 2008 , 17, 1039-50	5.9	4
148	Sustained complete molecular response after imatinib discontinuation in a patient with chronic myeloid leukemia not previously exposed to interferon alpha. <i>Leukemia and Lymphoma</i> , 2008 , 49, 1399-402	1.9	23
147	Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia. <i>Journal of the National Cancer Institute</i> , 2008 , 100, 184-98	9.7	295
146	Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia. <i>Blood</i> , 2008 , 111, 1834-9	2.2	255
145	Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-alpha treatment. <i>Blood</i> , 2008 , 111, 1039-43	2.2	175
144	Monitoring the response and course of chronic myeloid leukemia in the modern era of BCR-ABL tyrosine kinase inhibitors: practical advice on the use and interpretation of monitoring methods. <i>Blood</i> , 2008 , 111, 1774-80	2.2	112
143	The effects of imatinib on pregnancy outcome. <i>Blood</i> , 2008 , 111, 5505-8	2.2	256

142	Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation following failure of imatinib mesylate therapy. <i>Blood</i> , 2008 , 112, 53-5	2.2	111
141	BCR-ABL fusion transcript types and levels and their interaction with secondary genetic changes in determining the phenotype of Philadelphia chromosome-positive leukemias. <i>Blood</i> , 2008 , 112, 5190-2	2.2	28
140	Characteristics and outcome of chronic myeloid leukemia patients with F317L BCR-ABL kinase domain mutation after therapy with tyrosine kinase inhibitors. <i>Blood</i> , 2008 , 112, 4839-42	2.2	68
139	Phase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia. <i>Blood</i> , 2008 , 112, 981-9	2.2	222
138	Cytogenetic and molecular responses and outcome in chronic myelogenous leukemia: need for new response definitions?. <i>Cancer</i> , 2008 , 112, 837-45	6.4	91
137	Molecular basis explanation for imatinib resistance of BCR-ABL due to T315I and P-loop mutations from molecular dynamics simulations. <i>Cancer</i> , 2008 , 112, 1744-53	6.4	44
136	Therapeutic advances in leukemia and myelodysplastic syndrome over the past 40 years. <i>Cancer</i> , 2008 , 113, 1933-52	6.4	74
135	Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System. <i>Cancer</i> , 2008 , 113, 1351-61	6.4	386
134	Outcome of adults with acute lymphocytic leukemia after second salvage therapy. <i>Cancer</i> , 2008 , 113, 3186-91	6.4	103
133	Tailoring tyrosine kinase inhibitor therapy to tackle specific BCR-ABL1 mutant clones. <i>Leukemia Research</i> , 2008 , 32, 1313-6	2.7	9
132	Secondary myelodysplastic syndrome in a patient with Philadelphia-positive acute lymphoblastic leukemia after achieving a major molecular response with hyperCVAD plus imatinib mesylate. <i>Leukemia Research</i> , 2008 , 32, 1468-71	2.7	
131	Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes. <i>Blood</i> , 2008 , 111, 1060-6	2.2	397
130	A Phase I Study of XL019, a Selective JAK2 Inhibitor, in Patients with Primary Myelofibrosis, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis. <i>Blood</i> , 2008 , 112, 98-98	2.2	26
129	Targeted Therapy in Myelodysplastic Syndrome 2008 , 237-260		
128	Targeted Therapy in Chronic Myeloid Leukemia 2008 , 87-99		
127	Biology of Chronic and Acute Myeloid Leukemia 2008 , 371-383		
126	Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome. <i>Blood</i> , 2007 , 110, 2302-8	2.2	347
125	Scrotal Edema Associated with the Use of Dasatinib in Patients with Chronic Myeloid Leukemia. <i>Clinical Leukemia</i> , 2007 , 1, 357-358		

124	Management of patients with newly diagnosed chronic myeloid leukemia: opportunities and challenges. <i>Clinical Lymphoma and Myeloma</i> , 2007 , 7 Suppl 2, S51-7		2
123	Emerging safety issues with imatinib and other Abl tyrosine kinase inhibitors. <i>Clinical Lymphoma and Myeloma</i> , 2007 , 7 Suppl 3, S105-12		22
122	Phase I/II study of subcutaneous homoharringtonine in patients with chronic myeloid leukemia who have failed prior therapy. <i>Cancer</i> , 2007 , 109, 248-55	6.4	108
121	Activity of decitabine, a hypomethylating agent, in chronic myelomonocytic leukemia. <i>Cancer</i> , 2007 , 109, 713-7	6.4	106
120	Phase II study of low-dose decitabine in combination with imatinib mesylate in patients with accelerated or myeloid blastic phase of chronic myelogenous leukemia. <i>Cancer</i> , 2007 , 109, 899-906	6.4	115
119	Survival advantage with decitabine versus intensive chemotherapy in patients with higher risk myelodysplastic syndrome: comparison with historical experience. <i>Cancer</i> , 2007 , 109, 1133-7	6.4	158
118	Outcome of patients with Philadelphia chromosome-positive chronic myelogenous leukemia post-imatinib mesylate failure. <i>Cancer</i> , 2007 , 109, 1556-60	6.4	75
117	Novel tyrosine kinase inhibitor therapy before allogeneic stem cell transplantation in patients with chronic myeloid leukemia: no evidence for increased transplant-related toxicity. <i>Cancer</i> , 2007 , 110, 340-4	6.4	57
116	Phase 1 study of lonafarnib (SCH 66336) and imatinib mesylate in patients with chronic myeloid leukemia who have failed prior single-agent therapy with imatinib. <i>Cancer</i> , 2007 , 110, 1295-302	6.4	46
115	The prognosis for patients with chronic myeloid leukemia who have clonal cytogenetic abnormalities in philadelphia chromosome-negative cells. <i>Cancer</i> , 2007 , 110, 1509-19	6.4	97
114	Flying under the radar: the new wave of BCR-ABL inhibitors. <i>Nature Reviews Drug Discovery</i> , 2007 , 6, 834-48	6.4	246
113	Biphenotypic acute leukaemia: a case series. <i>British Journal of Haematology</i> , 2007 , 138, 213-6	4.5	47
112	Second-generation tyrosine kinase inhibitors as therapy for chronic myeloid leukemia. <i>Current Hematologic Malignancy Reports</i> , 2007 , 2, 83-8	4.4	2
111	New approaches to the management of Philadelphia-chromosome-positive acute lymphocytic leukemia. <i>Current Hematologic Malignancy Reports</i> , 2007 , 2, 183-9	4.4	1
110	Prognostic nomogram and index for overall survival in previously untreated patients with chronic lymphocytic leukemia. <i>Blood</i> , 2007 , 109, 4679-85	2.2	264
109	A pilot study of imatinib, low-dose cytarabine and idarubicin for patients with chronic myeloid leukemia in myeloid blast phase. <i>Leukemia and Lymphoma</i> , 2007 , 48, 283-9	1.9	40
108	The daunting task of modeling response to imatinib therapy in patients with chronic myelogenous leukemia. <i>Leukemia and Lymphoma</i> , 2007 , 48, 802-4	1.9	
107	Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure. <i>Journal of Clinical Oncology</i> , 2007 , 25, 3908-14	2.2	301

106	Important therapeutic targets in chronic myelogenous leukemia. <i>Clinical Cancer Research</i> , 2007 , 13, 1089-97	2.2	78
105	Congestive heart failure is a rare event in patients receiving imatinib therapy. <i>Blood</i> , 2007 , 110, 1233-7	2.2	205
104	Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. <i>Blood</i> , 2007 , 109, 52-7	2.2	577
103	MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation. <i>Blood</i> , 2007 , 109, 500-2	2.2	323
102	Dasatinib (BMS-354825) is active in Philadelphia chromosome-positive chronic myelogenous leukemia after imatinib and nilotinib (AMN107) therapy failure. <i>Blood</i> , 2007 , 109, 497-9	2.2	137
101	Plasma RNA as an alternative to cells for monitoring molecular response in patients with chronic myeloid leukemia. <i>Haematologica</i> , 2007 , 92, 170-5	6.6	17
100	Optimal initial therapy for patients with newly diagnosed chronic myeloid leukemia in chronic phase. <i>Current Opinion in Internal Medicine</i> , 2007 , 14, 138-44		1
99	Current perspectives on the treatment of patients with chronic myeloid leukemia: an individualized approach to treatment. <i>Cancer Journal (Sudbury, Mass)</i> , 2007 , 13, 357-65	2.2	5
98	New targeted therapies for chronic myelogenous leukemia: opportunities to overcome imatinib resistance. <i>Seminars in Hematology</i> , 2007 , 44, S25-31	4	23
97	Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis. <i>Blood</i> , 2007 , 109, 3207-13	2.2	354
96	Chromosomal abnormalities in Philadelphia chromosome negative metaphases appearing during imatinib mesylate therapy in patients with newly diagnosed chronic myeloid leukemia in chronic phase. <i>Blood</i> , 2007 , 110, 2991-5	2.2	114
95	Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors. <i>Blood</i> , 2007 , 110, 4005-11	2.2	247
94	Dasatinib for the treatment of Philadelphia chromosome-positive leukaemias. <i>Expert Opinion on Investigational Drugs</i> , 2007 , 16, 679-87	5.9	28
93	FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia. <i>Journal of Clinical Investigation</i> , 2007 , 117, 2408-21	15.9	270
92	INCB018424, an Oral, Selective JAK2 Inhibitor, Shows Significant Clinical Activity in a Phase I/II Study in Patients with Primary Myelofibrosis (PMF) and Post Polycythemia Vera/Essential Thrombocythemia Myelofibrosis (Post-PV/ET MF).. <i>Blood</i> , 2007 , 110, 558-558	2.2	17
91	New Therapies for Chronic Myeloid Leukemia 2007 , 165-184		
90	The clinical challenge of imatinib resistance in chronic myeloid leukemia: emerging strategies with new targeted agents. <i>Targeted Oncology</i> , 2006 , 1, 186-196	5	10
89	A retrospective comparison of three sequential groups of patients with Recurrent/Refractory chronic lymphocytic leukemia treated with fludarabine-based regimens. <i>Cancer</i> , 2006 , 106, 337-45	6.4	56

88	Phase II study of sphingosomal vincristine in patients with recurrent or refractory adult acute lymphocytic leukemia. <i>Cancer</i> , 2006 , 106, 120-7	6.4	73
87	Long-term follow-up results of the combination of topotecan and cytarabine and other intensive chemotherapy regimens in myelodysplastic syndrome. <i>Cancer</i> , 2006 , 106, 1099-109	6.4	89
86	Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia. <i>Cancer</i> , 2006 , 106, 1569-80	6.4	441
85	Activity of 9-nitro-camptothecin, an oral topoisomerase I inhibitor, in myelodysplastic syndrome and chronic myelomonocytic leukemia. <i>Cancer</i> , 2006 , 107, 1525-9	6.4	26
84	Advances in the therapy of chronic idiopathic myelofibrosis. <i>Oncologist</i> , 2006 , 11, 929-43	5.7	22
83	A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies. <i>Clinical Cancer Research</i> , 2006 , 12, 4628-35	12.9	288
82	Pregnancy among patients with chronic myeloid leukemia treated with imatinib. <i>Journal of Clinical Oncology</i> , 2006 , 24, 1204-8	2.2	183
81	Targeting ABL and SRC kinases in chronic myeloid leukemia: experience with dasatinib. <i>Future Oncology</i> , 2006 , 2, 655-65	3.6	16
80	Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. <i>New England Journal of Medicine</i> , 2006 , 354, 2531-41	59.2	1414
79	New insights into the pathophysiology of chronic myeloid leukemia and imatinib resistance. <i>Annals of Internal Medicine</i> , 2006 , 145, 913-23	8	187
78	Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. <i>Blood</i> , 2006 , 108, 28-37	2.2	977
77	Phase 1/2 study of the combination of 5-aza-2Pdeoxycytidine with valproic acid in patients with leukemia. <i>Blood</i> , 2006 , 108, 3271-9	2.2	441
76	Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. <i>Blood</i> , 2006 , 108, 1809-20	2.2	998
75	Dasatinib: A Dual ABL and SRC Inhibitor 2006 , 59-68		
74	Sudden blastic transformation in patients with chronic myeloid leukemia treated with imatinib mesylate. <i>Blood</i> , 2006 , 107, 480-2	2.2	53
73	Clofarabine and cytarabine combination as induction therapy for acute myeloid leukemia (AML) in patients 50 years of age or older. <i>Blood</i> , 2006 , 108, 45-51	2.2	132
72	Allogeneic stem cell transplantation for patients with chronic myeloid leukemia and acute lymphocytic leukemia after Bcr-Abl kinase mutation-related imatinib failure. <i>Blood</i> , 2006 , 108, 1421-3	2.2	77
71	Survival benefit with imatinib mesylate versus interferon-alpha-based regimens in newly diagnosed chronic-phase chronic myelogenous leukemia. <i>Blood</i> , 2006 , 108, 1835-40	2.2	181

70	International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT). <i>Blood</i> , 2006 , 108, 1497-503	2.2	287
69	Myelodysplastic syndromes and acute leukemia developing after imatinib mesylate therapy for chronic myeloid leukemia. <i>Blood</i> , 2006 , 108, 2811-3	2.2	130
68	Novel tyrosine kinase inhibitors in chronic myelogenous leukemia. <i>Current Opinion in Oncology</i> , 2006 , 18, 578-83	4.2	21
67	Overcoming drug resistance in chronic myeloid leukemia. <i>Current Opinion in Hematology</i> , 2006 , 13, 79-86	3.3	16
66	Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. <i>New England Journal of Medicine</i> , 2006 , 354, 2542-51	59.2	1133
65	New strategies in chronic myeloid leukemia. <i>International Journal of Hematology</i> , 2006 , 83, 289-93	2.3	20
64	A Phase 1/2 Study of SKI-606, a Dual Inhibitor of Src and Abl Kinases, in Adult Patients with Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia (CML) or Acute Lymphocytic Leukemia (ALL) Relapsed, Refractory or Intolerant of Imatinib.. <i>Blood</i> , 2006 , 108, 168-168	2.2	26
63	Pleural Effusion in Patients (pts) with Chronic Myelogenous Leukemia (CML) Treated with Dasatinib after Imatinib Failure.. <i>Blood</i> , 2006 , 108, 2164-2164	2.2	4
62	Chronic myeloid leukemia: current application of cytogenetics and molecular testing for diagnosis and treatment. <i>Mayo Clinic Proceedings</i> , 2005 , 80, 390-402	6.4	46
61	Results of a phase 1-2 study of clofarabine in combination with cytarabine (ara-C) in relapsed and refractory acute leukemias. <i>Blood</i> , 2005 , 105, 940-7	2.2	193
60	Imatinib mesylate therapy may overcome the poor prognostic significance of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemia. <i>Blood</i> , 2005 , 105, 2281-6	2.2	92
59	Significance of myelofibrosis in early chronic-phase, chronic myelogenous leukemia on imatinib mesylate therapy. <i>Cancer</i> , 2005 , 104, 777-80	6.4	22
58	AMN107, a novel aminopyrimidine inhibitor of p190 Bcr-Abl activation and of in vitro proliferation of Philadelphia-positive acute lymphoblastic leukemia cells. <i>Cancer</i> , 2005 , 104, 1230-6	6.4	69
57	Targeting the kinase activity of the BCR-ABL fusion protein in patients with chronic myeloid leukemia. <i>Current Molecular Medicine</i> , 2005 , 5, 615-23	2.5	28
56	Phase I evaluation of a 40-kDa branched-chain long-acting pegylated IFN-alpha-2a with and without cytarabine in patients with chronic myelogenous leukemia. <i>Clinical Cancer Research</i> , 2005 , 11, 6247-55	12.9	30
55	AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, has in vitro activity against imatinib-resistant chronic myeloid leukemia. <i>Clinical Cancer Research</i> , 2005 , 11, 4941-7	12.9	189
54	Phase II study of low-dose decitabine in patients with chronic myelogenous leukemia resistant to imatinib mesylate. <i>Journal of Clinical Oncology</i> , 2005 , 23, 3948-56	2.2	259
53	Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate. <i>Clinical Cancer Research</i> , 2005 , 11, 3425-32	12.9	237

52	Phase I study of cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, combined with cytarabine in patients with refractory leukemia. <i>Clinical Cancer Research</i> , 2005 , 11, 7817-24	12.9	28
51	Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. <i>Journal of Clinical Oncology</i> , 2005 , 23, 4070-8	2.2	447
50	Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. <i>Journal of Clinical Oncology</i> , 2005 , 23, 4079-88	2.2	811
49	New targeted approaches in chronic myeloid leukemia. <i>Journal of Clinical Oncology</i> , 2005 , 23, 6316-24	2.2	45
48	Investigational agents in myeloid disorders. <i>Advances in Pharmacology</i> , 2004 , 51, 59-97	5.7	
47	Survival advantage with imatinib mesylate therapy in chronic-phase chronic myelogenous leukemia (CML-CP) after IFN-alpha failure and in late CML-CP, comparison with historical controls. <i>Clinical Cancer Research</i> , 2004 , 10, 68-75	12.9	49
46	New agents in acute myeloid leukemia and other myeloid disorders. <i>Cancer</i> , 2004 , 100, 441-54	6.4	34
45	Granulocyte-colony-stimulating factor (filgrastim) may overcome imatinib-induced neutropenia in patients with chronic-phase chronic myelogenous leukemia. <i>Cancer</i> , 2004 , 100, 2592-7	6.4	53
44	Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia. <i>Cancer</i> , 2004 , 101, 2788-801	6.4	461
43	Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2Pdeoxycytidine (decitabine) in hematopoietic malignancies. <i>Blood</i> , 2004 , 103, 1635-40	2.2	694
42	Natural history and staging of chronic myelogenous leukemia. <i>Hematology/Oncology Clinics of North America</i> , 2004 , 18, 569-84, viii	3.1	65
41	Clonal evolution in chronic myelogenous leukemia. <i>Hematology/Oncology Clinics of North America</i> , 2004 , 18, 671-84, x	3.1	67
40	High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia. <i>Blood</i> , 2004 , 103, 2873-8	2.2	344
39	Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate. <i>Blood</i> , 2004 , 103, 4396-407	2.2	458
38	Outcome with the hyper-CVAD regimens in lymphoblastic lymphoma. <i>Blood</i> , 2004 , 104, 1624-30	2.2	202
37	Discontinuation of imatinib therapy after achieving a molecular response. <i>Blood</i> , 2004 , 104, 2204-5	2.2	253
36	Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia. <i>Blood</i> , 2003 , 101, 473-5	2.2	273
35	Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies. <i>Blood</i> , 2003 , 101, 3413-5	2.2	220

34	Result of high-dose imatinib mesylate in patients with Philadelphia chromosome-positive chronic myeloid leukemia after failure of interferon-alpha. <i>Blood</i> , 2003 , 102, 83-6	2.2	164
33	Rituximab in relapsed or refractory hairy cell leukemia. <i>Blood</i> , 2003 , 102, 3906-11	2.2	127
32	Fractionated cyclophosphamide, vincristine, liposomal daunorubicin, and dexamethasone plus rituximab and granulocyte-macrophage-colony stimulating factor (GM-CSF) alternating with methotrexate and cytarabine plus rituximab and GM-CSF in patients with Richter syndrome or fludarabine-refractory chronic lymphocytic leukemia. <i>Cancer</i> , 2003 , 97, 1711-20	6.4	94
31	Results of imatinib mesylate therapy in patients with refractory or recurrent acute myeloid leukemia, high-risk myelodysplastic syndrome, and myeloproliferative disorders. <i>Cancer</i> , 2003 , 97, 2760-6	6.4	96
30	Treatment of Philadelphia chromosome-positive chronic myelogenous leukemia with weekly polyethylene glycol formulation of interferon-alpha-2b and low-dose cytosine arabinoside. <i>Cancer</i> , 2003 , 97, 3010-6	6.4	9
29	Chronic myelogenous leukemia: a review and update of therapeutic strategies. <i>Cancer</i> , 2003 , 98, 437-57	6.4	61
28	Results of decitabine (5-aza-2'-deoxycytidine) therapy in 130 patients with chronic myelogenous leukemia. <i>Cancer</i> , 2003 , 98, 522-8	6.4	200
27	Results of triple therapy with interferon-alpha, cytarabine, and homoharringtonine, and the impact of adding imatinib to the treatment sequence in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in early chronic phase. <i>Cancer</i> , 2003 , 98, 888-93	6.4	62
26	Effects of age on prognosis with imatinib mesylate therapy for patients with Philadelphia chromosome-positive chronic myelogenous leukemia. <i>Cancer</i> , 2003 , 98, 1105-13	6.4	74
25	Chromosomal abnormalities in Philadelphia chromosome-negative metaphases appearing during imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase. <i>Cancer</i> , 2003 , 98, 1905-11	6.4	114
24	Imatinib mesylate therapy improves survival in patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia in the chronic phase: comparison with historic data. <i>Cancer</i> , 2003 , 98, 2636-42	6.4	77
23	Alemtuzumab as treatment for residual disease after chemotherapy in patients with chronic lymphocytic leukemia. <i>Cancer</i> , 2003 , 98, 2657-63	6.4	186
22	Advanced-phase chronic myeloid leukemia. <i>Seminars in Hematology</i> , 2003 , 40, 79-86	4	37
21	Comments on the Hammersmith policy. <i>Seminars in Hematology</i> , 2003 , 40, 105-106	4	
20	Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia. <i>Blood</i> , 2003 , 102, 2379-86	2.2	281
19	Phase I clinical and pharmacology study of clofarabine in patients with solid and hematologic cancers. <i>Journal of Clinical Oncology</i> , 2003 , 21, 1167-73	2.2	168
18	Hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone and highly active antiretroviral therapy for patients with acquired immunodeficiency syndrome-related Burkitt lymphoma/leukemia. <i>Cancer</i> , 2002 , 94, 1492-9	6.4	123
17	The role of local radiation therapy for mediastinal disease in adults with T-cell lymphoblastic lymphoma. <i>Cancer</i> , 2002 , 94, 2738-44	6.4	44

16	CD56 expression predicts occurrence of CNS disease in acute lymphoblastic leukemia. <i>Leukemia Research</i> , 2002 , 26, 643-9	2.7	48
15	Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase. <i>Blood</i> , 2002 , 99, 3547-53	2.2	251
14	New agents in the treatment of acute lymphocytic leukaemia. <i>Best Practice and Research in Clinical Haematology</i> , 2002 , 15, 771-90	4.2	7
13	Response to therapy is independently associated with survival prolongation in chronic myelogenous leukemia in the blastic phase. <i>Cancer</i> , 2001 , 92, 2501-7	6.4	19
12	Central nervous system involvement in adult acute lymphocytic leukemia. <i>Hematology/Oncology Clinics of North America</i> , 2001 , 15, 145-62	3.1	43
11	Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia. <i>Journal of Clinical Oncology</i> , 2001 , 19, 1414-20	2.2	299
10	Rituximab dose-escalation trial in chronic lymphocytic leukemia. <i>Journal of Clinical Oncology</i> , 2001 , 19, 2165-70	2.2	527
9	Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia. <i>Journal of Clinical Oncology</i> , 2000 , 18, 547-61	2.2	616
8	Homoharringtonine and low-dose cytarabine in the management of late chronic-phase chronic myelogenous leukemia. <i>Journal of Clinical Oncology</i> , 2000 , 18, 3513-21	2.2	73
7	Outcome of Philadelphia chromosome-positive adult acute lymphoblastic leukemia. <i>Leukemia and Lymphoma</i> , 2000 , 36, 263-73	1.9	121
6	Treatment of Philadelphia chromosome-positive early chronic phase chronic myelogenous leukemia with daily doses of interferon alpha and low-dose cytarabine. <i>Journal of Clinical Oncology</i> , 1999 , 17, 284-92	2.2	126
5	Hyper-CVAD program in BurkittB-type adult acute lymphoblastic leukemia. <i>Journal of Clinical Oncology</i> , 1999 , 17, 2461-70	2.2	213
4	Chronic myelogenous leukaemia with p185(BCR/ABL) expression: characteristics and clinical significance. <i>British Journal of Haematology</i> , 1999 , 107, 581-6	4.5	47
3	Primary refractory and relapsed adult acute lymphoblastic leukemia: characteristics, treatment results, and prognosis with salvage therapy. <i>Cancer</i> , 1999 , 86, 1216-30	6.4	153
2	Chronic myelogenous leukemia in nonlymphoid blastic phase: analysis of the results of first salvage therapy with three different treatment approaches for 162 patients. <i>Cancer</i> , 1999 , 86, 2632-41	6.4	143
1	Standard Management of Patients with Chronic Myeloid Leukemia71-85		